October 21st 2024
Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the agent in consultation with the FDA.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Docetaxel Continues to Show Profound Benefits in Prostate Cancer
January 14th 2017Targeted therapies and immunotherapy are revolutionizing oncology, however, chemotherapy retains a key role in the treatment of advanced prostate cancer, with recent data showing profound benefits with docetaxel in newly diagnosed patients.
Read More
Adding Enzalutamide to Dual Androgen Blockade Fails to Improve PFS in mCRPC
December 29th 2016The addition of enzalutamide to abiraterone acetate and prednisone failed to improve progression-free survival versus abiraterone and prednisone alone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer who progressed on enzalutamide.
Read More
Surgery, RT, or Active Surveillance for Localized Prostate Cancer: An Expert Discusses
November 8th 2016Bertram Yuh, MD, discussed the selection of surgery or radiation therapy in patients with localized disease, as well as the potential for using active surveillance with these patients.
Read More
Lau Talks Controversy Surrounding PSA Biomarker in Prostate Cancer Screening
November 2nd 2016Clayton S. Lau, MD, highlights the importance of active surveillance, the evolution of surgical techniques and radiation therapy, and the steps oncologists should take once early-stage prostate cancer progresses.
Read More
Cabozantinib Plus Nivolumab Shows Second-Line Promise in GU Cancers
November 1st 2016The combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) in patients with advanced/refractory genitourinary cancers demonstrated promising activity in the second-line setting and beyond at all dose levels tested.
Read More
FDA Updates Enzalutamide Label in mCRPC Based on New Study Findings
October 25th 2016The FDA has updated the label for enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC) to include new data from the phase II TERRAIN study, according to the codevelopers of the androgen receptor inhibitor, Astellas and Pfizer.
Read More
Study Shows H-RT Is Safe, Effective for Low-Risk Prostate Cancer
October 21st 2016Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy (H-RT) is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.
Read More
CVS Cuts Out In-House Dispensaries of Cancer Drugs
October 20th 2016A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs, the Community Oncology Alliance (COA) argued in a new white paper.
Read More
No Benefit from Combined Irradiation in Intermediate-Risk Prostate Cancer
October 7th 2016The addition of external-beam radiotherapy (EBRT) to interstitial brachytherapy failed to reduce prostate cancer progression compared to brachytherapy alone in men with intermediate-risk disease, interim data from a randomized trial showed.
Read More
Advances in Image-Guided Oncologic Treatment
September 21st 2016Advances in the computerization of the imaging, blood flow, and tumor measures of exact volume and vessel density are now less operator dependent. That provides for an accurate and repeatable diagnosis, and a means to follow the individual patient’s unique pattern of cancer development, progress, and response to treatment.
Read More
EC Approves Lenvatinib in Combination With Everolimus for RCC
September 19th 2016The European Commission (EC) has granted its approval for lenvatinib (Kisplyx; EU) in combination with everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC) following 1 prior VEGF-targeted therapy.
Read More
Expert Discusses Sequential Therapy Benefits for Patients With Muscle-Invasive Bladder Cancer
September 8th 2016Though the current standard of care when treating muscle-invasive bladder cancer calls for neoadjuvant chemotherapy followed by radical cystectomy, the procedure is associated with a fair amount of morbidity and is not suggested lightly, according to Stanley Yap, MD.
Read More
Rio Grande Urology Partners With Gynecologic Oncologist
September 7th 2016As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it. It was formed by 4 urology practices merging to build a main campus that houses the cancer center and radiation therapy center.
Read More
An Overview of the ALSYMPCA Study in Metastatic Prostate Cancer
September 1st 2016Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, gives an overview of the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study, and he discusses ongoing trials examining the use of radium-223 dichloride (Xofigo) in metastatic castration-resistant prostate cancer (mCRPC).
Watch